Category Pharma/Biotech

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

Bristol Myers Squibb announced the first disclosure of primary analysis results from two pivotal studies, TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with…

Read MoreBristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

Lannett Successfully Emerges From Chapter 11 in Significantly Stronger Financial Position as the Company Remains on Track Toward Commercialization of Highly Promising Pipeline

Lannett Company, Inc. (the “Company” or “Lannett”) today announced that it and certain of its subsidiaries have successfully emerged from their Chapter 11 cases following the confirmation of its Plan…

Read MoreLannett Successfully Emerges From Chapter 11 in Significantly Stronger Financial Position as the Company Remains on Track Toward Commercialization of Highly Promising Pipeline

Biological Dynamics Case Report Published in Frontiers in Oncology Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions

Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for earlier disease detection, today announced the publication of a case report, “Early detection of pancreatic…

Read MoreBiological Dynamics Case Report Published in Frontiers in Oncology Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions

Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)

Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial. At 90 days post-Debridement, Antibiotics, and Implant Retention (DAIR)…

Read MorePeptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)